<DOC>
	<DOC>NCT00103935</DOC>
	<brief_summary>Exenatide LAR is a long-acting release formulation of exenatide, which is a twice-daily dosage form currently under investigation as a potential treatment for people with type 2 diabetes mellitus. This study will assess the safety, tolerability, and pharmacokinetics of Exenatide LAR administered weekly by subcutaneous injection in people with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Has type 2 diabetes treated with either: *A stable regimen of metformin for a minimum of 3 months, and/or *Diet modification and exercise for a minimum of 3 months. Has HbA1c of 7.1% to 11.0%, inclusive. Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive. Received any investigational drug within 3 months prior to screening. Is currently treated with any of the following excluded medications: *Thiazolidinediones within 3 months of screening; * Sulfonylureas within 3 months of screening; * Insulin within 1 year of screening. Participated previously in an exenatide clinical study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>diabetes</keyword>
	<keyword>exenatide</keyword>
	<keyword>long acting release</keyword>
	<keyword>Amylin</keyword>
	<keyword>Lilly</keyword>
</DOC>